Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

-- Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of Stage 1 Safety and Tolerability Data -- -- The Stage 2 Portion of VAX-24 Infant Study Will Include...

Related Keywords

United States ,Jennifer Zibuda ,Janet Graesser ,Jim Wassil ,Groupa Strep ,Nasdaq ,Drug Administration ,Company Expects To Announce Topline Data ,Advisory Committee On Immunization Practices ,Corporate Communications ,Exchange Commission ,Sutro Biopharma Inc ,Vaxcyte Inc ,Study Will Include Prevnar ,Announce Topline Data ,Primary Immunization Series ,Topline Data ,Booster Dose Approximately Nine Months ,Data Safety Monitoring Board ,Grant Pickering ,Chief Executive Officer ,Advisory Committee ,Immunization Practices ,Executive Vice President ,Chief Operating ,Sutro Biopharma ,Private Securities Litigation Reform Act ,Quarterly Report ,Vice President ,Senior Director ,Investor Relations ,Markets ,